医药及疫苗股受捧 国药(01099.HK)及复星医药(02196.HK)续升8%及20%
新冠疫苗股今早全面跑赢,尤其是复星医药(02196.HK)回落收市始终守稳20天线,今早延续上周五弹势,突破10天线(51.36元)後,升幅扩大,最高见61.35元,暂受制上周二盘中所创纪录高位62.5元,现造59.95元,急涨20%,成交已达1,539万股。复星医药公布,与BioNTech订立协议,为新冠疫苗产品本地化生产和商业化设立一家合营各持一半权益,复星出资不超1亿美元,另公司会再对合营提供不超1.5亿欧元股东贷款及为合营银行融资提供支持。
世卫总干事谭德塞表示,将国药新冠疫苗列入世卫紧急使用清单。国药控股(01099.HK)承上周五升势,今早股价升破10天线(24.9元),最高见27.2元,暂受制上周二盘中所创逾一年高位27.6元,现造26.15元,续升8%,成交已达1,009万股。
康希诺生物-B(06185.HK)扭五连跌,今早股价重越50天线(317.4元),最高见329.8元,现造321.8元,回升6%。开拓药业-B(09939.HK)扭四连跌,今早股价曾重越10天线(69元),最高见70.85元,现造67.5元,回升7.1%。
内地第五批药品集采今天(10日)起开始信息申报,涉及202个品规。药明康德(02359.HK)、蓝筹石药(01093.HK)、药明生物(02269.HK)及中生制药(01177.HK)依次升2%-4.5%,後者最强,股价一举重越10天、20天及50天线曾高见8.42元。四环医药(00460.HK)扭三连跌,高见2.87元,现造2.81元,回升4.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.